Fig. 8
From: Altered expression of ACOX2 in non-small cell lung cancer
Associations between ACOX2 expression in NSCLC cell lines and differential anti-cancer drug sensitivity. Analysis of the CCLE database [50] demonstrated that lower ACOX2 mRNA expression differences were found to be associated with resistance to A Tanespimycin (HSP90 inhibitor), B PD-0235901 (MEK inhibitor) and C Crizotinib (c-MET/ALK inhibitor). A non-parametric Mann–Whitney test was used to assess for significance with p < 0.05 considered to be the threshold for significant. D Separate analysis of the DepMAp PRISM repurposing Primary Screen [52] also identified trametinib (GSK1120212) a separate MEK1/2 inhibitor as a potential candidate drug linked with ACOX2 expression